/PRNewswire/ – The board of directors of Eli Lilly and Company has elected Juan R. Luciano as a new member, effective February 1, 2016.
Luciano is chief executive officer and president of Archer Daniels Midland Company (ADM), and a member of the ADM board of directors.
“I am pleased to welcome Juan to the Lilly board,” said John C. Lechleiter, Ph.D., chairman, president and chief executive officer. “Juan brings to the Lilly board a global perspective and a proven track record of leading high-performance, results-focused organizations. We will benefit from Juan’s broad business experience, including his knowledge of the food and agriculture sectors.”
Luciano joined ADM in 2011 as executive vice president and chief operating officer. He was named president in February 2014, and in January 2015 became the ninth chief executive in ADM’s 112-year history.
Since joining ADM, Luciano has overseen the commercial and production activities of ADM’s Corn, Oilseeds and Agricultural Services businesses, as well as its research, project management, procurement and risk management functions. He led the company’s operational excellence initiatives, which seek to improve productivity and efficiency companywide, as well as the company’s efforts to improve its capital, cost and cash positions. Luciano also led the company’s move into ingredients.
Before joining ADM, Luciano had a successful 25-year tenure at The Dow Chemical Company, where he last served as executive vice president and president of the performance division.
Luciano is a governor of the Boys and Girls Clubs of America, and Midwest chair of the organization’s National Trustees Board. He holds an industrial engineering degree from the Buenos Aires Institute of Technology.
Source: Eli Lilly and Company
Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.
Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.
Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.
